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ANCA-positive systemic vasculitides, rare in paediatric age, present multiorganic involvement. A female teenager presented with
a history of subglottic stenosis diagnosed at the age of 12. From the investigation carried out, we highlight hematoproteinuria and
negative ANCAs. At 15 years old, she was admitted for gastrointestinal symptoms and respiratory distress. She presented poor
peripheral perfusion, pulmonary haemorrhage, respiratory failure, and severe renal insu1ciency. She was started mechanical
ventilation and emergency haemodialysis. (e immunological study revealed ANCA MPO positive. A presumptive diagnosis of
ANCA-positive vasculitis was made, and she was started corticotherapy, cyclophosphamide, and plasmapheresis. A renal biopsy,
performed later, showed crescentic glomerulonephritis with chronicity signs. Positive ANCA vasculitis may progress slowly or
suddenly. (e diagnosis was con3rmed by a biopsy; however, we can make a presumptive diagnosis based on clinical 3ndings and
in a positive ANCA test in order to start an early treatment and decrease the associated morbimortality.
1. Introduction
Vasculitides are disorders characterized by in6ammation
of the blood vessel that may occur as a primary process
or secondary to an underlying disease. Apart from com-
mon vasculitides such as Henoch–Schonlein purpura and
Kawasaki disease, most of the primary vasculitic syndromes
are rare in childhood [1–4].
(e antineutrophil cytoplasmic antibody- (ANCA-)
associated vasculitides (AAV) are a group of chronic,
multiorgan, and often relapsing diseases [3, 5]. (e three
classic AAV are granulomatosis with polyangiitis (GPA),
microscopic polyangiitis (MPA), and eosinophilic gran-
ulomatosis with polyangiitis (EGPA).
EGPA is an eosinophilic-rich necrotizing vasculitis,
exceedingly rare in childhood, characterized by chronic
rhinosinusitis, asthma, and peripheral blood eosinophilia
[4, 6]. In EGPA, ANCA is found in a minority of children [4].
GPA is characterized by a necrotizing granulomatous
small and medium vessel vasculitis, and it mainly aCects
older children [3, 4, 7]. Patients often present constitutional
symptoms (88%), renal involvement (83%), lower respira-
tory disease (74%), and upper airways/ear, nose, and throat
involvement (70%) [7]. GPA is frequently related with
antibody directed against proteinase 3 (PR3) that stains
neutrophils in a cytoplasmic fashion (c-ANCA) [4, 7, 8].
MPA is a necrotizing nongranulomatous vasculitis that
aCects small size blood vessels [3, 4, 9]. (is disease aCects
children signi3cantly younger than those that GPA aCects
[7]. Comparatively to GPA, almost all children have con-
stitutional symptoms (85%) in MPA; however, pulmonary
manifestations are less frequent (44%) and less severe [7].
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Renal involvement is also frequent (75%) and tends to be
more severe than that in paediatric GPA [7]. In MPA,
contrary to GPA, the upper respiratory tract is spared [4, 7].
MPA is commonly associated with elevated titers of ANCA
directed at myeloperoxidase (MPO) that lead to perinuclear
staining of neutrophils (p-ANCA) [4, 7, 8].
Although GPA is primarily associated with PR3-ANCA
and MPA with MPO-ANCA, about 25% of the patients with
GPA or MPA have the alternative ANCA [10].
(e priorities in the management of a child with AAV
are the prompt recognition and early treatment, as these
diseases can be severe and life-threatening if not appro-
priately managed [11]. (e diagnosis of AAV is strongly
suggested by a positive ANCA test; however, 5–10% of the
patients do not develop ANCA, so a negative result does not
exclude a diagnosis of AAV [8, 11]. (e biopsy of an aCected
organ remains the most de3nitive method to establish
a diagnosis [8, 11]. Treatment comprises remission induc-
tion, with initial immunosuppressive therapy and mainte-
nance immunosuppressive therapy for a variable period to
prevent relapse [4, 5, 8, 9, 11].
Despite treatment, AAV still carries considerable
disease-related morbidity and mortality mainly due to
progressive renal failure or aggressive respiratory involve-
ment [5, 6, 9].
2. Case Presentation
A 3fteen-year-old female was transferred to the intensive
paediatric care unit due to pulmonary haemorrhage, re-
quiring mechanical ventilation, and renal insu1ciency.
She has no relevant family history and has neonatal
antecedents of extreme prematurity and bronchopulmonary
dysplasia.
At eleven years of age, she started having episodes of
respiratory distress, wheezing, coughing, and stridor that
lead to multiple hospitalizations despite therapy with β2
long-acting agonists, antileukotrienes, and inhaled corti-
costeroids. In the exacerbations, she presented weak re-
sponse to salbutamol and improvement with adrenaline and
methylprednisolone. In this context, an etiological in-
vestigation was carried out at the hospital in her residential
area: negative allergy screening; normal immunoglobulin
and complement levels; normal alpha-1 antitrypsin level;
negative sweat test; negative Ziehl–Neelsen staining and
Mycobacterium tuberculosis culture in gastric juice; and
normal upper gastrointestinal endoscopy, esophageal-
gastroduodenal transit, and thoracic computed tomography.
At twelve years old, she developed progressive dysphonia
showing no improvement with oral and inhaled cortico-
steroids. She was observed in otolaryngology consultation at
a central hospital: the chest radiograph showed the steeple
sign (Figure 1) and the broncho3broscopy revealed a pleated
and hardened supraglottic mucosa and subglottic stenosis.
Firstly, she underwent laser surgery, and two months later,
an emergency tracheotomy for respiratory insu1ciency.
After the tracheostomy, she needed reinterventions due to
the worsening of the subglottic stenosis. From the in-
vestigation carried out in this hospital, we highlight normal
angiotensin-converting enzyme level, negative antinuclear
antibodies (ANA), negative ANCA (by a combination of
both indirect immuno6uorescence technique (IFT) and
enzyme-linked immunosorbent assays (ELISAs) for PR3 and
MPO), the presence of hematoproteinuria (proteins 5mg/dl
and erythrocytes> 25/3eld), mild changes in renal function
(creatinine 0.86mg/dl and glomerular 3ltration rate
65ml/min/1.73m2), and laryngeal biopsy with squamous
epithelial hyperplasia and polymorphic in3ltrate, without
granulomas or malignancy signs.
At fourteen, the laboratory investigation was repeated at
an otolaryngology consultation that disclosed the worsening
of hematoproteinuria (proteins 150mg/dl and eryth-
rocytes> 38/µl) and renal function (creatinine 0.98mg/dl
and urea 44mg/dl), and positivity for ANCA antibodies
(IFT: ANCA 1/320, p-ANCA pattern; ELISA: anti-MPO
37RU/ml, anti-PR3 1.4 RU/ml—normal range< 20 RU/ml).
Four months later, at the age of 3fteen, she was admitted
to the hospital in her residential area with a history of
abdominal pain, vomiting, diarrhoea, di1culty in breath-
ing and coughing for the past two days, and one-month
history of aphonia. Examination 3ndings revealed apyrexia,
pallor, poor peripheral perfusion, and di1culty in breath-
ing with global retraction and bilateral crepitations at
pulmonary auscultation. She also presented hypertension
(144/99mmHg), generalized mild oedema, oliguria, and
bleeding through the tracheostomy hole. Initial investiga-
tions revealed mixed acidosis (pH 7.01; pCO2 62.3mmHg;
HCO3 15.5mmol/L; and lactate 1.1mmol/L), severe anaemia
with normal leukocyte and platelet accounts (haemoglobin
5.3 g/dl; leukocytes 12.700/uL; and platelets 318.000/uL),
severe renal impairment (urea 339mg/dl and creatinine
18mg/dl), and hyperkalaemia (7.18mmol/L). (e remaining
ionogram, liver function, coagulation screen, and C-reactive
protein were within normal limits. (e chest radiograph
disclosed diCused opacity with ill-de3ned edges (like cotton
wool) in the lower half of both lung 3elds, and ultrasound
revealed moderate left pleural eCusion. Bronchoscopy
revealed bronchial serohematic content.
(e patient’s condition deteriorated rapidly, and she was
transferred to the intensive paediatric care unit, in our
hospital, for respiratory and renal support.
In the intensive paediatric care unit, while reviewing the
patient’s electronic clinical process, we detected previous
Figure 1: Chest radiograph showed the steeple sign.
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analyses that had not been valued. Given the clinical picture
of renal failure with hematoproteinuria associated with
pulmonary haemorrhage with positive MPO-ANCA, a pre-
sumptive diagnosis of vasculitis anti-MPO ANCA positive
was made, and she immediately started treatment with
daily methylprednisolone (650mg/day) and support measures
(red blood cells concentrate, antihypertensives, sodium bi-
carbonate, calcium gluconate, salbutamol, and insulin) and
haemodialysis. On the fourth day of treatment, methylpred-
nisolone was changed to oral prednisolone (1mg/kg/day) and
she started oral cyclophosphamide (2mg/kg/day) and plasma
exchange for seven days. She also received prophylactic
cotrimoxazole.
From the laboratorial investigation carried out in the
intensive paediatric care unit, we highlight immunoglobulins
and C4 within normal values, C3 slightly decreased
(77.1mg/dl), negative anti-glomerular basement membrane
antibodies, negative ANA, and positive ANCA MPO (IFT:
ANCA 1/640, p-ANCA pattern; ELISA: anti-MPO 55.8UQ,
anti-PR3 14.6UQ—normal range< 20UQ). (oracic com-
puted tomography showed areas with a bilateral ground glass
appearance and hilar adenomegalies. Echocardiogram
revealed a small pericardial eCusion without further changes.
(e patient was ventilated for a total of 13 days and
remained clinically stable with progressive hypertension
control and with no new episodes of pulmonary haemor-
rhage. She maintained oligoanuric renal insu1ciency with
the need of dialysis treatment. A renal biopsy was per-
formed, and the histologic examinations revealed crescentic
glomerulonephritis with a strong 3brosis degree. A pauci-
immune pattern was observed in immuno6uorescence
microscopy.
On the thirty-third day of hospitalization, cyclophos-
phamide treatment was suspended due to leukopenia
and induction therapy was started with rituximab
(750mg/m2/dose, two doses with 3fteen-day breaks). She
was discharged after 36 days of hospitalization with oral
prednisolone that was slowly tapered.
Currently, half a year later, she maintains haemodialysis
therapy; however, she has improved from the tracheal ste-
nosis allowing her better vocal quality.(ere were no further
complications. (e ANCA became negative with reduction
of the anti-MPO concentration to <2.3UQ (normal
range< 20UQ).
3. Discussion
AAV are rare in the paediatric age and can progress slowly
over months or explosively over days. In this case report, the
long period between the onset of symptoms and the di-
agnosis clearly illustrates the di1culty faced in recognizing
AAV.
(e respiratory symptoms, present since she was eleven
years old, constituted an early manifestation of the disease.
Nevertheless, the diagnosis of tracheal stenosis was only
made six months later, after the development of dysphonia.
After this diagnosis, an etiological investigation was car-
ried out at the otolaryngology centre and they found
hematoproteinuria and mild renal insu1ciency that was not
properly valued since the immunological study was normal.
Later, the investigation was repeated, and she presented
a worsening of hematoproteinuria and renal function with
positive ANCA. Nonetheless, these results were not valued
before the life-threatening episode observed in the admission.
In the intensive care unit, a presumptive diagnosis of
MPO-ANCA-positive vasculitis was made, allowing for the
start of immediate treatment. Later, a renal biopsy was
performed, and it was compatible with the previous pre-
sumptive diagnosis; however, unfortunately a high chro-
nicity degree was also observed, and the patient was
considered with end-stage renal disease.
Classi3cation criteria of vasculitides were developed in
order to standardize clinical de3nitions of diCerent vascu-
litides but not to diagnose disease in individuals [12].(e goal
was to de3ne homogeneous populations to facilitate clinical
research studies. Once childhood vasculitides are rare, ex-
perience of individual physicians in diagnosing and caring for
children with chronic vasculitis is also limited, as was rec-
ognized by Ozen in an survey in which the median number of
patients with an AAV diagnosed by any rheumatologist in
a single year was <1 [13]. (us, clinicians with limited ex-
perience to these particular conditions may use classi3cation
criteria to assist in the diagnosis of individual patients [13, 14].
(e 3rst classi3cation criteria, and most widely used, were
developed by the American College of Rheumatology (ACR);
however, these criteria are based upon data from adult pa-
tients [15]. Once some individual criteria are more frequent or
characteristic of childhood presentation (like subglottic ste-
noses in GPA) [16], the European League Against Rheu-
matism (EULAR) and the Paediatric Rheumatology European
Society (PRES) proposed in 2005 a system of classi3cation for
vasculitides in children, which was validated in 2008
(EULAR/PRINTO/PRES criteria) [17, 18]. Unfortunately, due
to the few cases of the less frequent forms of AAV in their
population, classi3cation criteria were not developed for
MPA. EuropeanMedicines Agency (EMA) to attempt to solve
these limitations developed an algorithm which includes a list
of surrogate markers for GPA, re6ecting those features most
typical of GPA not occurring in MPA, like subglottic stenosis
[19]. (ereby, this algorithm in a sequential manner applies
diCerent criteria (including ACR or EULAR/PRINTO/PRES
criteria for GPA), de3nitions, and surrogate markers, from
most speci3c to least speci3c, in a stepwise approach allowing
the diCerentiation between CSS, GPA, and MPA [19].
Applying EULAR/PRINTO/PRES criteria, we can a1rm
that our patient has GPA (she ful3lls four out of six GPA
criteria—upper respiratory tract involvement, laryngo-
tracheobronchial obstruction, lung involvement, ANCA
positivity, and renal involvement—and only three criteria
are required for the diagnosis) [17]. Although GPA is typ-
ically associated with PR3-ANCA, MPO-ANCA can be
found in about 25% of these patients [10]. (us, the presence
of MPO-ANCA does not rule out GPA diagnosis as shown
by the EULAR/PRINTO/PRES criteria that only included in
their criteria ANCA positivity, which could be for MPO or
PR3 [17].
(e goal of AAV therapy is the induction of complete
remission which is de3ned as the absence of active disease.
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Initial immunosuppressive therapy in AAV typically con-
sists of glucocorticoids combined with either cyclophos-
phamide or rituximab [4]. In our case, and in addition to this
therapy, plasmapheresis was also performed, as this child
had pulmonary haemorrhage and severe renal insu1ciency
with the need for dialysis [4, 20, 21]. In this case report, and
despite the child maintaining end-stage renal disease after
induction immunosuppressive therapy, she presented tra-
cheal and pulmonary disease remission and ANCA titers
declined to become negative. (ere are controversies about
the role of ANCA titers in determining e1cacy of treatment
and in the prediction of the development of a relapse. (e
absence of ANCA is usually evidence against a 6are, but the
opposite is not true [4].
(ere is little knowledge about the optimal treatment of
AAV patients who developed severe renal insu1ciency.
(ese patients have less probability of responding to therapy
compared with preserved renal function patients and ad-
ditionally present an increased risk for immunotherapy
adverse eCects. A recent study with patients requiring di-
alysis at the time of diagnosis showed that, in the absence of
active extrarenal vasculitis, continued immunosuppressive
therapy beyond four months is very unlikely to bene3t
patients who remain dependent on dialysis [22].(us, in this
case, due to the need of dialysis therapy since the admission
and the strong chronicity degree observed in kidney biopsy,
we decided not to administer maintenance immunosup-
pressive therapy.
(e authors intend to point out the di1culty in di-
agnosing AAV and distinguishing between these diseases, as
they are rare in paediatric age, their clinical features and
serologies often overlap, and they have a varied clinical
course, which is sometimes indolent. In this case, the di-
agnosis was even more di1cult since the serologies were
initially negative, and the child was monitored in diCerent
centres which may have hampered the clinical data in-
tegration. Although the classi3cation criteria for AAV were
not elaborated for the purpose of individual diagnosis, given
the rarity and di1culty of diagnosing these diseases, they
could be used by physicians for diagnosis when their ex-
perience with patients with AAV is limited [13, 14].
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